Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer

摘要: Neuroendocrine differentiation of tumor tissue has been recognized as an important prerequisite for new targeted therapies. To evaluate the suitability colorectal cancer (CRC) these treatment approaches and to find a possible link pretherapeutic conditions other strategies, we compared neuroendocrine KRAS/NRAS/BRAF/PIK3CA/TP53 mutational status in primary metastatic CRC. Immunohistochemical expression analysis markers chromogranin A synaptophysin was performed on archival CRC tissue, comprising 116 tumors, 258 lymph node metastases 72 distant from 115 patients. All samples but 30 were subjected mutation KRAS, NRAS, BRAF, PIK3CA, TP53. marker found significantly less frequently tumors (20%, 31%, 28%, respectively, P = 0.044). KRAS rates increased within negative group (44%, 53%, 64%, 0.042). concordant than tumor/lymph pairs (65% versus 88%-99%; < 0.0001) tumor/distant (64% 83%-100%; 0.027 0.0001, respectively). According data, therapeutic targeting cells can be considered only subset patients biopsies site should used guide therapy. importance lacking progression mutant further investigated.